Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744713 | 0.93 | CHRM4 (0.47) | CHRM2CHRM1PRKAA2CHRM3CHRM5 | |
| SCHEMBL23744703 | 0.91 | CHRM2 (0.49) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL26429677 | 0.89 | HSD11B1 (0.38) | CXCR3CHRM2CHRM1PRKAA2CHRM3 | |
| SCHEMBL26434902 | 0.88 | CHEK2 (0.46) | CXCR3CHRM4CHEK2 | |
| SCHEMBL26434941 | 0.84 | CHRM2 (0.57) | CXCR3CHRM2CHRM1PRKAA2CHRM3 | |
| SCHEMBL23744741 | 0.84 | CHRM2 (0.57) | CXCR3CHRM2CHRM1PRKAA2CHRM3 | |
| SCHEMBL26429655 | 0.82 | CHRM4 (0.39) | CHRM2CHRM1PRKAA2CHRM3CHRM5 | |
| SCHEMBL23744655 | 0.81 | CHRM4 (0.47) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL23744456 | 0.81 | CHRM4 (0.47) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL23744735 | 0.81 | HRH3 (0.43) | CHRM2PRKAA2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CXCR3 281/4885CHRM2 2/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.